Toyoshi T, Ukai M, Kameyama T
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.
Biol Pharm Bull. 1996 Mar;19(3):369-74. doi: 10.1248/bpb.19.369.
The effects of intracerebroventricular (i.c.v.) injection of the mu-selective opioid receptor agonist [D-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) and the kappa-selective opioid receptor agonist dynorphin A-(1-13) on the development of methamphetamine-induced behavioral sensitization in the mouse were determined using multidimensional behavioral analyses based upon a capacitance system. Methamphetamine (2 mg/kg, s.c.) was administered to mice on 6 occasions at 3- or 4-d intervals. The methamphetamine-induced increase in linear locomotion and circling was markedly augmented by repeated administrations (3 or more times) of the drug, showing behavioral sensitization. Although repeated administrations of DAMGO (0.003 and 0.01 microgram, i.c.v.) or dynorphin A-(1-13) (3 and 12.5 micrograms, i.c.v.) alone did not produce any significant effects on behavior, repeated administrations of DAMGO (0.003 and 0.01 microgram, i.c.v.) and dynorphin A-(1-13) (3 and 12.5 micrograms, i.c.v.) attenuated the behavioral sensitization induced by methamphetamine (2 mg/kg, s.c.). The attenuating effects of DAMGO (0.003 and 0.01 microgram, i.c.v.) and dynorphin A-(1-13) (3 and 12.5 micrograms, i.c.v.) were fully reversed by withdrawal of these drugs for 3 weeks. Additionally, a single administration of DAMGO (0.003 and 0.01 microgram, i.c.v.) or dynorphin A-(1-13) (3 and 12.5 micrograms, i.c.v.) alone did not produce any significant effects on behavior; DAMGO (0.003 and 0.01 microgram, i.c.v.) and dynorphin A-(1-13) (3 and 12.5 micrograms, i.c.v.) only attenuated the behavioral sensitization which had previously been developed by methamphetamine (2 mg/kg,s.c.). These results suggest that opioid receptor agonists selective for mu and kappa receptors play an inhibitory role in the development of methamphetamine-induced behavioral sensitization.
利用基于电容系统的多维行为分析,确定了脑室内(i.c.v.)注射μ-选择性阿片受体激动剂[D-Ala2,N-MePhe4,Gly-ol]脑啡肽(DAMGO)和κ-选择性阿片受体激动剂强啡肽A-(1-13)对小鼠甲基苯丙胺诱导的行为敏化发展的影响。以3或4天的间隔给小鼠6次注射甲基苯丙胺(2mg/kg,皮下注射)。药物重复给药(3次或更多次)显著增强了甲基苯丙胺诱导的直线运动和转圈增加,表现出行为敏化。虽然单独重复注射DAMGO(0.003和0.01微克,i.c.v.)或强啡肽A-(1-13)(3和12.5微克,i.c.v.)对行为没有产生任何显著影响,但重复注射DAMGO(0.003和0.01微克,i.c.v.)和强啡肽A-(1-13)(3和12.5微克,i.c.v.)减弱了甲基苯丙胺(2mg/kg,皮下注射)诱导的行为敏化。DAMGO(0.003和0.01微克,i.c.v.)和强啡肽A-(1-13)(3和12.5微克,i.c.v.)的减弱作用在停药3周后完全逆转。此外,单独单次注射DAMGO(0.003和0.01微克,i.c.v.)或强啡肽A-(1-13)(3和12.5微克,i.c.v.)对行为没有产生任何显著影响;DAMGO(0.003和0.01微克,i.c.v.)和强啡肽A-(1-13)(3和12.5微克,i.c.v.)仅减弱了先前由甲基苯丙胺(2mg/kg,皮下注射)产生的行为敏化。这些结果表明,对μ和κ受体具有选择性的阿片受体激动剂在甲基苯丙胺诱导的行为敏化发展中起抑制作用。